| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | P21; CIP1; SDI1; WAF1; CAP20; CDKN1; MDA-6; p21CIP1 |
| WB Predicted band size | 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CDKN1A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CDKN1A(p21)抗体的参考文献及其摘要概括：
1. **文献名称**: "p21 in cancer: intricate networks and multiple activities"
**作者**: Abbas T, Dutta A
**摘要**: 该综述探讨了CDKN1A/p21在肿瘤发生中的作用，提及使用特异性抗体通过免疫印迹和免疫组化揭示其在细胞周期阻滞和DNA修复中的调控机制。
2. **文献名称**: "A senescence-associated secretory phenotype regulated by p21"
**作者**: Coppé JP, et al.
**摘要**: 研究利用CDKN1A抗体进行蛋白质定位分析，发现p21通过调控衰老相关分泌表型(SASP)影响肿瘤微环境，抗体用于验证p21与衰老标记物的共表达。
3. **文献名称**: "CDKN1A/p21 mediates TGF-β-induced cell cycle arrest in human astrocytes"
**作者**: Romagosa C, et al.
**摘要**: 通过Western blot和免疫荧光(使用抗CDKN1A抗体)，证明TGF-β通过上调p21表达诱导人星形胶质细胞周期停滞，抗体用于检测蛋白水平变化。
4. **文献名称**: "Antibody-based profiling of cell cycle progression in human cancers"
**作者**: Geng Y, et al.
**摘要**: 开发了一种基于抗体的细胞周期蛋白检测方法，包括CDKN1A抗体，用于分析临床肿瘤样本中p21表达与化疗反应及预后的相关性。
CDKN1A (Cyclin-dependent kinase inhibitor 1A), also known as p21 or Cip1/Waf1. is a critical regulator of cell cycle progression and cellular stress responses. Encoded by the CDKN1A gene, this protein functions as a cyclin-dependent kinase (CDK) inhibitor, binding to and inhibiting the activity of CDK complexes to block cell cycle transition from G1 to S phase. Its expression is tightly controlled by the tumor suppressor p53 in response to DNA damage, oxidative stress, or oncogenic signals, making it a key mediator of p53-dependent cell cycle arrest, senescence, and apoptosis.
CDKN1A antibodies are essential tools for studying these biological processes in research. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to detect p21 protein levels, localization, and dynamics in various cell types and tissues. These antibodies help investigate CDKN1A's roles in cancer (as both tumor suppressor and therapy resistance factor), aging, and degenerative diseases. Specific antibody clones are validated for distinguishing p21 from related CDK inhibitors (e.g., p27. p16) and assessing post-translational modifications. Commercial CDKN1A antibodies often include validation data from knockout models or siRNA-treated samples to confirm specificity. Researchers also utilize them to explore crosstalk between p21 and other signaling pathways, such as TGF-β or Wnt, in development, differentiation, and stem cell regulation.
×
